- Home
- EDIT vs EM Comparison
EDIT vs EM Comparison
Compare EDIT & EM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- EM
- Stock Information
- Founded
- EDIT 2013
- EM 2017
- Country
- EDIT United States
- EM China
- Employees
- EDIT N/A
- EM N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- EM Other Consumer Services
- Sector
- EDIT Health Care
- EM Consumer Discretionary
- Exchange
- EDIT Nasdaq
- EM Nasdaq
- Market Cap
- EDIT 179.1M
- EM 289.1M
- IPO Year
- EDIT 2016
- EM 2021
- Fundamental
- Price
- EDIT $2.88
- EM $1.12
- Analyst Decision
- EDIT Buy
- EM Hold
- Analyst Count
- EDIT 12
- EM 1
- Target Price
- EDIT $6.20
- EM $1.25
- AVG Volume (30 Days)
- EDIT 3.5M
- EM 93.6K
- Earning Date
- EDIT 08-06-2025
- EM 08-21-2025
- Dividend Yield
- EDIT N/A
- EM N/A
- EPS Growth
- EDIT N/A
- EM N/A
- EPS
- EDIT N/A
- EM N/A
- Revenue
- EDIT $35,837,000.00
- EM $259,541,587.00
- Revenue This Year
- EDIT N/A
- EM $3.30
- Revenue Next Year
- EDIT N/A
- EM $5.26
- P/E Ratio
- EDIT N/A
- EM N/A
- Revenue Growth
- EDIT N/A
- EM N/A
- 52 Week Low
- EDIT $0.91
- EM $0.50
- 52 Week High
- EDIT $6.05
- EM $1.17
- Technical
- Relative Strength Index (RSI)
- EDIT 74.64
- EM 49.22
- Support Level
- EDIT $2.48
- EM $1.12
- Resistance Level
- EDIT $3.24
- EM $1.16
- Average True Range (ATR)
- EDIT 0.25
- EM 0.03
- MACD
- EDIT 0.07
- EM -0.00
- Stochastic Oscillator
- EDIT 84.84
- EM 16.67
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About EM Smart Share Global Limited
Smart Share Global Ltd is a consumer tech company providing mobile device charging services through an extensive online and offline network in China. It provides service through power banks, placed in POIs operated by location partners, such as entertainment venues, restaurants, shopping centers, hotels, transportation hubs, and public spaces. Geographically, the company generates revenue from the PRC. The company has two segments, the mobile device charging segment and the PV business segment. The company generates the majority of its revenue from the mobile device charging segment.